Organogenesis Holdings Inc. (ORGO)

Market Cap	526.33M
Revenue (ttm)	455.04M
Net Income (ttm)	-7.38M
Shares Out	132.58M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	72.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	464,504
Open	4.070
Previous Close	4.080
Day's Range	3.903 - 4.155
52-Week Range	2.165 - 4.705
Beta	1.60
Analysts	Strong Buy
Price Target	5.33 (+34.26%)
Earnings Date	Nov 12, 2024

About ORGO

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered li...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 862
• Stock Exchange: NASDAQ
• Ticker Symbol: ORGO
• Website: https://organogenesis.com

Financial Performance

In 2023, Organogenesis Holdings's revenue was $433.14 million, a decrease of -3.94% compared to the previous year's $450.89 million. Earnings were $4.95 million, a decrease of -68.16%.

Analyst Forecast

According to 3 analysts, the average rating for ORGO stock is "Strong Buy." The 12-month stock price forecast is $5.33, which is an increase of 34.26% from the latest price.

Price Target

$5.33

(34.26% upside)

Analyst Consensus: Strong Buy